Associate Manufacturing Scientist I (3rd Shift) jobs in United States
cer-icon
Apply on Employer Site
company-logo

Arrowhead Pharmaceuticals · 1 day ago

Associate Manufacturing Scientist I (3rd Shift)

Arrowhead Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative drugs that treat intractable diseases through RNA interference technologies. The Associate Manufacturing Scientist I will support the production of drug substances and products, primarily focusing on the preparation of solutions and reagents while ensuring compliance with GMP protocols.

BiotechnologyHealth CareNanotechnologyPharmaceutical
check
Comp. & Benefits
badNo H1Bnote

Responsibilities

Follow batch records, SOPs, and work instructions to detail
Document all operations in batch records and notebooks
Comply with GMP protocols
Assist other chemists within the CMC group during synthesis and chromatography of oligonucleotides including:
Reagent solution preparation
Column Packing
Mobile phase preparation
Fraction collection
Operate TFF to desalt purified RNA solutions
Operate a lyophilizer and package solid drug substance
Execute processes as part of a team to ensure production timelines are kept and quality product is produced
Maintain a clean work space
Maintain safety by wearing required personal protective equipment

Qualification

GMP protocolsChemistryBiochemistryReagent solution preparationTeam collaborationAttention to detailVerbal communicationWritten communication

Required

BS or MS in chemistry, biochemistry, engineering, or related scientific field
Entry level to 3 years experience in a similar position
Good verbal and written communication skills
Ability to work in a team environment
Ability to pay attention to detail

Preferred

Experience working in a GMP setting with controlled documentation

Benefits

Competitive salaries
Excellent benefit package

Company

Arrowhead Pharmaceuticals

twittertwittertwitter
company-logo
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.

Funding

Current Stage
Public Company
Total Funding
$1.62B
Key Investors
Sarepta TherapeuticsSixth StreetSilence Therapeutics
2024-11-26Post Ipo Equity· $325M
2024-08-08Post Ipo Debt· $400M
2024-01-03Post Ipo Equity· $450M

Leadership Team

leader-logo
Christopher Anzalone
President and Chief Executive Officer
leader-logo
Bruce Given
Chief Operating Officer
linkedin
Company data provided by crunchbase